|
|
|
Clinical trials offer patients access to promising new treatments which have not yet been approved. They offer an opportunity to help make new treatments available to all patients by helping to advance science. Patients in clinical trials receive high-quality care and are carefully followed. The IMF is pleased to offer a number of ways to help you locate a clinical trial which may be appropriate.
|
|
Before new drugs or procedures can be approved for use in treating myeloma, they must go through clinical trials to prove that they are safe and more effective than currently-available treatments
|
|
| |
A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic Bone and Multiple
Myeloma Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation |
|
|
|
|
| |
Carfilzomib is a new intravenously-administered proteasome inhibitor showing promise for the treatment of multiple myeloma. |
|
|
|
|
|
REVLIMID®, a potent immunomodulatory derivative (IMiD) of thalidomide, induces apoptosis in resistant MM cell lines and patient cells and, more importantly, decreases binding of MM cells to bone marrow stromal cells. |
|
|
|
|
|
|
|
Clinical trials using thalidomide. If you would like to know more about thalidomide treatment for myeloma, click on the "living with myeloma" tab at the top, and then on "Treatments." |
|
|
|
|
|
The latest on clinical trials using VELCADE®. If you would like to know more about VELCADE®, click on the 'information & treatments' tab at the top, and then on 'Treatments' in the index on the left hand side of the page." |
|
|
|
|
|
Cancer treatments, including chemotherapy and steroids, are associated with enhanced bone loss and increased fracture risk. This bone loss may lead to collapsed vertebrae in the spine, also known as vertebral body compression fractures (VCFs). The primary purpose of this study is to document how patients with VCFs function in every day activities after being treated with balloon kyphoplasty compared to those treated with non-surgical therapy alone. This information may help doctors treating cancer patients with broken backbones determine which treatment to recommend. |
|
|
|
|
| |
Vorinostat is an HDAC inhibitor, which has shown promise in the treatment of multiple myeloma. |
|
|
|
print
back to top